September 06, 2025

Get In Touch

Short Term Tamsulosin Therapy Effective For Reducing OAB Symptoms In Men: Study

Study on Tamsulosin for Overactive Bladder

Study on Tamsulosin for Overactive Bladder in Men

Atlanta, GA: Initiation of short course tamsulosin (α-blocker therapy) in men helps in reducing the symptoms of overactive bladder (OAB), finds a recent study in the journal Urology.

Theodore M. Johnson II, Emory University, Atlanta, GA, and colleagues aimed to evaluate tamsulosin therapy for male OAB and to examine if indicators of concomitant benign prostatic hyperplasia (BPH) cause improvement in OAB symptoms.

For the purpose, the researchers performed a planned, exploratory analysis of a 4-week, α-blocker (tamsulosin 0.4mg) run-in phase of the Male Overactive Bladder Trial in Veterans (MOTIVE). It included 116 male Veterans (aged 42-88 years) with urinary urgency and urinary frequency (> 8 voids / 24 hours). They were made to complete bladder diaries, answer symptom questionnaires (AUA-7 SI). Also, post-void residual and non-invasive uroflowmetry were measured.

Also Read: Behaviour therapy addition to Drugs effectively controls OAB Symptoms in Men: Study

Key Findings of the Study

  • There were statistically significant reductions in voiding frequency (11.3 to 10.0 voids/24 hours), urgency scores (mean 2.5 to 2.2 points), and nightly nocturia (2.1 to 1.8).
  • Only baseline AUA-7 SI total and voiding subscale categories (mild, moderate, severe) were associated with significant reduction in AUA-7 SI total score.
  • For continuous variables, only AUA-7 SI baseline total score was associated with AUA-7 SI storage symptom changes.
  • No other baseline measures were associated with changes in urgency, frequency, or nocturia.

"Our findings indicate that initiation of short course tamsulosin therapy in men was associated with statistical reduction in OAB symptoms," wrote the authors.

"Baseline post-void residual, uroflow rate, and the voiding symptom sub-score of the AUA-7 SI were not predictive of OAB symptom improvement with tamsulosin. These findings merit further exploration," they concluded.

Also Read: FDA approves vibegron for overactive bladder in adults

The study titled, "An exploratory analysis of tamsulosin for Overactive Bladder (OAB) in men with varying voiding symptom burden," is published in the journal Urology.

DOI: https://www.goldjournal.net/article/S0090-4295(21)00085-6/fulltext

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!